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Abstract
A 36-year-old man with fever and pancytopenia due
to Hemophagocytic Lymphohistiocytosis is reported.
The patient was started on the HLH-94 based treat
ment. Two weeks after the initiation of therapy the
patient’s pancytopenia had resolved and he was
discharged to complete treatment as an outpatient.
The initial clinical presentation, diagnostic criteria,
pathophysiology and treatment will be discussed,
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is a
rare syndrome seen almost exclusively in children
under five years of age.1’2The syndrome develops as
a result of an uncontrolled histiocyte activation and
proliferation into multiple organ systems. The syn
drome is defined by the presence of fever. cytopenia
(2 of3 cell lines). splenomegaly. hypolibrinogenemia
and/or hypertriglyceridemia and hemophagocytosis
seen on microscopic examination.3It develops either
from a primary, inherited condition know as Familial
Hemophagocytic Lymphohis tiocytosis (EHL) or a
secondarily acquired form. The latter are infection-
associated hemophagocytic syndrome (LAHS)caused
by any variety of bacterial, viral. fungal or parasitic
organisms, or malignancy-associated hemophago
cytic syndrome (MARS) typically associated with
acute lymphocytic leukemia or lymphoma. Although
the initial treatment is the same, the prognosis and
definitive treatments vary based on the underlying
etiology.
remainder of’ his physical exam was normal. Initial
laboratory studies were significant for an elevated Icr—
ntin of5873 ng/ml. librinogen 197 mg/dl. WBC 1700.
hemoglobin 10.4 g/dl, hematocrit 30.2k. platelet
count 16,000. LDH 998 U/L(normal range: 94-250).
Additional abnormal laboratory results include anAST
of 165 U/L (normal: 0-37), ALT: 87 (normal: 0-40).
alkaline phosphatase of 538 U/L (normal: 38-126)
and a conjugated bilirubin of 5.3 mg/dl.
Peripheral blood smear obtained on admission was
significant for leukopenia. neutropenia and thrombo
cytopenia. Bone marrow aspirate was remarkable for
normal cellularity without blasts. However, multiple
histiocytes were seen with ingested leukeocytes. eryth
rocytes and platelets. The diagnosis of Hemophago
cytic lymphohistiocytosis (HLH) was made based on
clinical presentation. the presence of all diagnostic
criteria (table I )‘ and the observation of phagocytic
histiocytecells on bone marrowbiopsy(figui-e I). The
patient was started on dexamethasone and etoposide
per the Hemophagocytic Lvmphohistiocytosis Study
Group-94 guidelines, as well as high-dose intrave
nous acyclovir. There was an immediate resolution
of the patient’s fever, and hemoglobin, platelet and
leukocyte counts demonstrated a brisk response to
the initial therapy. Peripheral blood PCR for Epstein
Barr virus (EBV) DNA was positive. He did not test
positive for any of the familial gene mutations. He
was discharged for completion of his chemotherapy
and antiviral course as an outpatient.
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Case Report
A36-year-old activeduty Navy Filipino man stationed
in Japan complainedofathree-day history of persistent
headache and fever to 104°F despite repeated doses
of acetaminophen. He had no ill contacts and no ro
dents or mosquitoes exposures. Initial work up at his
local medical clinic was unrevealing and the sailor
was sent home. Re returned the following day with
persistence of his fever, was found to be leukopenic
and was transferred to our medical center. His review
of systems was otherwise unremarkable and physi
cal exam was significant for splenomegaly without
peripheral adenopathy. No rash was noted and the
Discussion
Pathophysiology
Although the exact event that triggers activation of
the Natural Killer (NK) and Cvtotoxic T cells is not
clearly understood, it is theorized that an uncontrolled
expansion of polyclonal CD8 T lymphocytes and
subsequent cytokine storm cause the non-specific T
cell activation of macrophages! histiocytes:1Thi reac
tion results in the observed non—malignant invasion of
visceral organs. lymph nodes and bone marrow. The
non-specific activation also leads to phagocytosis of
all hematopoietic precursors by invading histiocytes.
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Excess production of TNF—a and a soluble Fas ligand
(CD95: a mediator tor cellular apoptosis) cause the
tissue damage and inliammation seen specifically in
the liver and spleen.
In Familial HEFT, there is an inherited loss of func
tion in N/Kcytotoxic T cells. The most frequent gene
mutations seen in FHLH are in the Perform Gene
PRF— I I 0q 21
—221. a gene fordirect cellular killing)
and a mutation in Ch 9q2 1.3—22. 1 cell dysfunction
is a constant feature of primar HER and does not
change atler treatment with HLH-94 protocol. This
is an important distinction as it has consequences on
treatment success.’
In EBV associated HER it is believed that infection
of T cells results in the overproduction of cytokines
IL-I, 2, 6, 10. interferon gamma and TNF-a, which
cause excessive acti\ ation of macrophage cell lines.5
In all etiologies, researchers find macrophages with
increased expression of CD-36, a key phagocytosis
receptor with a lack of antigen presenting ability.6
Diagnostic Criteria
Hemophagocytic Lymphohistiocytosis (HLH) is a
syndrome defined by the presence of five findings:
Hepatic dysfunction is present in 74 percent of cases.
Additional findings that have been proposed to assist
in diagiosis are: low/absent NK-cell activity: serum
ferritin >500,ug!L. and soluble CD25 (slL-2 receptor)
>2400 U/mI. In patients with neurologic involvement.
apredominance ofmononuclearcells in the CSF with
chronic inflammatory changes on liver biopsy and
reduced natural killer activity is also highly sugges
tive of the syndrome.
Patients may notmeetall diagnostic criteriaon initial
presentation, so retesting is essential. This is pal-ticu—
larl important in the evaluation for hemophagocytic
histiocytes. Initial bone marrow biopsies may be in
conclusive so it is recommended that repeated samples
be taken. Alternatively, spleen, lymph nodes and or
liver biopsies are recommended if clinical suspicion
is high and initial bone marrow biopsy is negative.3
Treatment
Initial management: During the evaluation for HLH syndrome and continuing into
the initial treatment it is essential to provide basic supportive care. This includes
repiacementofredblood cells, platelets, and fIbrinogen. These corrections are often
short-lived secondary to hypersplenism and fever. Maintenance of neutropenic
precautions and aggressive treatment of all infections is also important. Currently,
initial treatment with chemotherapy is the standard. This treatment focuses on the
immune suppression and disruption of the aberrant signaling pathways. RLH-94
treatment protocol consists of an initial eight weeks of biweekly etoposide doses
and a dexamethasone taper. During weeks 10 through 52 the patient receives eto
poside and dexameihasone pulse every other week and twice daily Cyclosporine
A with a target serum concentration of 100 mcg/L.
In secondary HLH syndrome the causative etiology needs to he identitied and ad
dressed. Primary HLH syndrome will require bone marrow transplant fordeumnitie
treatment, since relapse after treatment occurs in all cases.1 Identification of the
underlying cause of this syndrome is essential as primary and secondary disease
have different end points. Furthermore, among the infectious etiolog.. the EBV
etiologies differ in that these patients have a worse prognosis. as compared to all
other infections.
Summary
Hernophagocytic Lymphohistiocytosis isarare disease seen primarily in children
with one study estimating the incidence to be 1.2 cases in I niiIlion. Although
this syndrome is an uncommon cause of pancytopenia. the diagnosis of HLH
should be considered especially in the setting of hepatic dysfunction and splenic
enlargement. The prognosis is poor if the syndrome is not promptly treatedmedian
survival withoLit treatment of two months). In addition, most forms o1 secondary
HLII syndrome are very amenable to treatment. It is also important to remember
that although the syndrome is defined by the presence of five criteria, all markers
may not he present on presentation. In the absence of any one specific clinical
marker and a high clinical suspicion. therapy should commence immediately and
testing should continue. Diagnostic work up and treatment of possible under
lying malignancy such as acute lymphocytic leukemia, myeloma, lymphorna.
See Hemophagocytic Lymphohistiacytosis, p. 277
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Table 1.— Dtagnostic Criteria for Hemophagocytic
Lymphohtstiocytosis
1. Persistent fever, seen in 60-100% of cases
2. Cytopenia affecting two of the three cell lines: seen in 82-
100% of cases
3. Splenomegaly: seen in 35-100% of cases
4. Hypofibrinogenemia: seen in 19-85% of cases and/or hypertri
glyceridemia: seen in 59100% of cases
5. Hemophagocytosis as seen on bone biopsy : 100% (required
for diagnosisl
Henwphagocvtic Lymphohistiocytosix. Th’m p. 263
and carcinoma or determining the causative infectious agent is critical as well. It is also
important to remember that the presence of EBV virus or other inlectious agents does not
preclude underivinD FHLH and genetic testing is recommended for all cases,. Lltimatelv
in [-HLH. atter initial treatment with the chemotherapy, the ultimate curative therapy is
allogeneic hone marrow transplant. Our patient has done very well and is completing his
therap\. without return of the syndrome.
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Classified Notices
To place a classified notice:
HMA members.—Asabenefitof membership. HMA
members may place a complimentary one-time clas
sified ad in HMJ as space is available.
Nonmembers—Rates are $1.50 a word with a
minimum of 20 words or $30. Not commissionable.
For more information call i808) 536-7702,
Office Space
MEDICAL / DENTAL /HEALTHCARE RELATED
— OFFICE SPACES AVAILABLE in Kalihi, Excellent
location next to banks and restaurants at the corner
of North King and Gulick in Central Honolulu Medical
Clinic Building with air conditioning, free parking for
patients and customers (41 total stalls),nextto main bus
line, competative rates, and many patientslf interested,
please contact Jan Kim at 441-0521 or 942-7100.
SHEP, /rom p. 270
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Until there’s a cure
there’s the
American Diabetes
Association.
Office Space & Support Services
ALA MOANA BLDG.— PHYSICIAN WANTED to share space
and supportservices. Interestin physical rehab.preferred.We
have unique time-share arrangements starting at one half-day
per week. Run your practice wth no fixed overhead. Contact
Dr. Speers. REHABILITATION ASSOCIATES. 955-7244.
Aloha Laboratories, Inc
when results counts
A CAP accredited laboratory
Quality and Service
David M. Amberger, M.D.
liBest Doctors in Americafl
Laboratory Director
Phone (808) 842-6600
Fax (808) 848-0663
results@alohalabs.com
wwwalohalabs.com
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